KM Research Hub

REVIEW LEDGER

论文复核台

集中查看元数据入排不确定项,以及已识别 KM 但需确认 No. at risk 的内容复核项。

论文元数据入排图像/No. at risk 复核依据
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.PMID 39197072 · 2024-Dec-05eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.PMID 39282896 · 2024-Dec-05eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients.PMID 39792424 · 2024-Dec-01eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial.PMID 38582650 · 2024-Deceligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse.PMID 39241959 · 2024-Deceligible命中用户提供的消化道肿瘤阳性参考集。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial.PMID 39241963 · 2024-Deceligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.PMID 39289145 · 2024-Deceligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.PMID 39306585 · 2024-Deceligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
5-Fluorouracil metabolic pathway genes predict recurrence risk following adjuvant S-1 therapy: Results of an ancillary analysis from a phase III trial of resected biliary tract cancer (JCOG1202A1).PMID 39318258 · 2024-Deceligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Immunological impact of intraperitoneal and intravenous chemotherapy in ovarian cancer, translational analyses of the Phase 3 iPocc trial.PMID 39413557 · 2024-Deceligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study.PMID 39486165 · 2024-Deceligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study.PMID 39489924 · 2024-Deceligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study.PMID 39520835 · 2024-Deceligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial.PMID 39549720 · 2024-Deceligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial.PMID 39557058 · 2024-Deceligible命中用户提供的消化道肿瘤阳性参考集。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.PMID 39604725 · 2024-Deceligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.PMID 39282906 · 2024-Nov-28eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.PMID 39602630 · 2024-Nov-28eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.PMID 39580202 · 2024-Nov-23eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018).PMID 39186709 · 2024-Nov-20eligible命中用户提供的消化道肿瘤阳性参考集。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.PMID 39550172 · 2024-Nov-16eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Preoperative Chemoradiotherapy for Resectable Gastric Cancer.PMID 39282905 · 2024-Nov-14eligible命中用户提供的消化道肿瘤阳性参考集。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.PMID 39282910 · 2024-Nov-14eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.PMID 38828984 · 2024-Nov-07eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.PMID 38899716 · 2024-Nov-07eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Application of Recombinant Human Superoxide Dismutase in Radical Concurrent Chemoradiotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Acute Rectal Injury: A Multicenter, Randomized, Open-label, Prospective Trial.PMID 38705489 · 2024-Nov-01needs_reviewTrial meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result. However, it is excluded because the primary and secondary endpoints are focused on the incidence and duration of radiation-induced acute rectal injury (diarrhea) and mucosal damage, which are safety/toxicity endpoints, not a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR reporting.pending-Trial meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result. However, it is excluded because the primary and secondary endpoints are focused on the incidence and duration of radiation-induced acute rectal injury (diarrhea) and mucosal damage, which are safety/toxicity endpoints, not a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR reporting.
Semen analysis and reproductive hormones in boys with classical Hodgkin lymphoma treated according to the EuroNet-PHL-C2 protocol.PMID 39256932 · 2024-Nov-01needs_reviewThe record is an add-on study to a randomized phase-3 trial evaluating a drug-containing chemotherapy regimen for Hodgkin lymphoma in boys. However, it is not an original result report of the trial's primary efficacy endpoint (e.g., OS, PFS). Instead, it is a secondary analysis focusing on reproductive toxicity (semen parameters, hormones), which is a safety/quality-of-life-related outcome, not a primary time-to-event efficacy endpoint required for inclusion.pending-The record is an add-on study to a randomized phase-3 trial evaluating a drug-containing chemotherapy regimen for Hodgkin lymphoma in boys. However, it is not an original result report of the trial's primary efficacy endpoint (e.g., OS, PFS). Instead, it is a secondary analysis focusing on reproductive toxicity (semen parameters, hormones), which is a safety/quality-of-life-related outcome, not a primary time-to-event efficacy endpoint required for inclusion.
Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study.PMID 39088774 · 2024-Noveligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial.PMID 39159638 · 2024-Noveligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study.PMID 39230871 · 2024-Noveligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial.PMID 39250926 · 2024-Noveligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.PMID 39259927 · 2024-Noveligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer.PMID 39284383 · 2024-Noveligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.PMID 39288737 · 2024-Noveligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
The immunotherapy-based combination associated score as a robust predictor for outcome and response to combination of immunotherapy and VEGF inhibitors in renal cell carcinoma.PMID 39341105 · 2024-Noveligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.PMID 38832972 · 2024-Oct-31eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2).PMID 39519198 · 2024-Oct-30eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review已识别 KM 曲线,但未在图像中识别到 No. at risk 表,需人工复核正文或补充材料。已识别 KM 曲线,但未在图像中识别到 No. at risk 表,需人工复核正文或补充材料。
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.PMID 39426385 · 2024-Oct-26eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.PMID 38924756 · 2024-Oct-24eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial.PMID 39419054 · 2024-Oct-19eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.PMID 39268857 · 2024-Oct-10eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.PMID 39288779 · 2024-Oct-05eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy with Helical TomoTherapy Versus Conventional Radiation Therapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer Receiving Concurrent Chemotherapy: A Multicenter, Randomized Phase 3 Trial.PMID 38631536 · 2024-Oct-01eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation.PMID 39243304 · 2024-Sepneeds_reviewThe study is a randomized Phase III trial of a drug (asciminib) in human oncology (CML-CP) with original results. However, the primary efficacy endpoint is major molecular response rate (a categorical response rate), not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, or TTP. The abstract does not mention Kaplan-Meier analysis, hazard ratios, or any time-to-event outcome, so it fails the time-to-event criterion.pending-The study is a randomized Phase III trial of a drug (asciminib) in human oncology (CML-CP) with original results. However, the primary efficacy endpoint is major molecular response rate (a categorical response rate), not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, or TTP. The abstract does not mention Kaplan-Meier analysis, hazard ratios, or any time-to-event outcome, so it fails the time-to-event criterion.
A Prospective Randomized Multicenter Study on the Impact of [18F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer.PMID 38844361 · 2024-Jul-01needs_reviewThe study meets criteria for oncology, human subjects, randomized design, Phase III status, and time-to-event endpoints. However, the primary intervention is a diagnostic imaging agent/procedure, not a drug-containing therapeutic intervention. Therefore, it is excluded.pending-The study meets criteria for oncology, human subjects, randomized design, Phase III status, and time-to-event endpoints. However, the primary intervention is a diagnostic imaging agent/procedure, not a drug-containing therapeutic intervention. Therefore, it is excluded.
The Influence of Surgical Complexity and Center Experience on Postoperative Morbidity After Minimally Invasive Surgery in Gynecologic Oncology: Lessons Learned from the ROBOGYN-1004 Trial.PMID 38616209 · 2024-Julneeds_reviewThe metadata confirms an oncology, human, randomized, Phase III trial, but the reported outcome is postoperative morbidity, not a survival or time-to-event efficacy endpoint. Therefore, it is not eligible for the Kaplan-Meier digitization cohort.pending-The metadata confirms an oncology, human, randomized, Phase III trial, but the reported outcome is postoperative morbidity, not a survival or time-to-event efficacy endpoint. Therefore, it is not eligible for the Kaplan-Meier digitization cohort.
Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021;5(23):5098-5106.PMID 38743412 · 2024-May-14needs_reviewTitle and metadata indicate a randomized Phase III oncology trial with a drug intervention, but the abstract is not provided and no time-to-event signal (OS, PFS, DFS, HR, Kaplan-Meier) is detected in the provided metadata. Cannot confirm human subjects or that this is an original result report (vs. update, erratum, etc.).pending-Title and metadata indicate a randomized Phase III oncology trial with a drug intervention, but the abstract is not provided and no time-to-event signal (OS, PFS, DFS, HR, Kaplan-Meier) is detected in the provided metadata. Cannot confirm human subjects or that this is an original result report (vs. update, erratum, etc.).
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.PMID 38062124 · 2024-Marneeds_reviewThe study is a secondary analysis of pooled Phase III trials in multiple myeloma, focusing on morbidity and mortality during induction therapy. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or hazard ratio data.pending-The study is a secondary analysis of pooled Phase III trials in multiple myeloma, focusing on morbidity and mortality during induction therapy. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or hazard ratio data.
Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.PMID 38229199 · 2024-Jan-16needs_reviewThis is a protocol paper for an ongoing phase 3 randomized trial in oncology with a time-to-event endpoint (PFS), but it does not report completed trial results. The drug intervention involves CAM2029 (octreotide subcutaneous depot) versus standard-of-care somatostatin receptor ligands (octreotide LAR or lanreotide), which are drugs, but the abstract does not provide efficacy results from the completed trial. It is not an original formal result report.pending-This is a protocol paper for an ongoing phase 3 randomized trial in oncology with a time-to-event endpoint (PFS), but it does not report completed trial results. The drug intervention involves CAM2029 (octreotide subcutaneous depot) versus standard-of-care somatostatin receptor ligands (octreotide LAR or lanreotide), which are drugs, but the abstract does not provide efficacy results from the completed trial. It is not an original formal result report.
A phase III randomized controlled trial comparing local field with additional prophylactic irradiation in chemoradiotherapy for clinical-T1bN0M0 esophageal cancer: ARMADILLO trial (JCOG1904).PMID 37801434 · 2024-Jan-07needs_reviewThis is a protocol for an ongoing Phase III randomized trial in oncology with a primary time-to-event endpoint, but it does not present results. The eligibility criteria require original formal-result reports of completed trials. Additionally, the drug intervention (specific chemotherapy agent(s)) is not explicitly detailed in the provided record, which is needed to confirm a drug-containing intervention.pending-This is a protocol for an ongoing Phase III randomized trial in oncology with a primary time-to-event endpoint, but it does not present results. The eligibility criteria require original formal-result reports of completed trials. Additionally, the drug intervention (specific chemotherapy agent(s)) is not explicitly detailed in the provided record, which is needed to confirm a drug-containing intervention.